About 17 percent of workforce
Belgian Pharma UCB Announces Across-the-World Job Cuts
08/28/2008
Belgium´s UCB announced it would be cutting about 17 percent of its workforce, a previously reported plan in order to tighten up expenditure to offset loss of sales from products going off-patent. CEO Roch Doliveux talks of shaping the company´s future. Further details.
On New England Journal of Medicine site
Stroke Prevention Studies: Neither Hypertension nor Blood Thinner Drugs Help
08/28/2008
Two studies reveal neither a hypertension drug (telmisartan) nor a blood thinner (dipyridamole) worked in preventing the recurrence of strokes, questioning their advantage over using the standard anti-clotting treatment clopidogrel, or in fact, no drug at all, as the data of patients on placebo showed. The studies were posted on the New England Journal of Medicine site. Further details.
Vaccine candidate against staphylococcus aureus infections
Intercell AG and Merck & Co Announce Start of Second Phase II Clinical Trial for V710
08/28/2008
Intercell AG today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. The trial start follows the initiation of a separate Phase II trial in December 2007.
Retigabine
GlaxoSmithKline and Valeant Sign Alliance for Rights to Experimental Epilepsy Drug
08/28/2008
U.K.´s GlaxoSmithKline Plc has signed a deal potentially worth up to $ 820 million dollars with U.S. Valeant Pharmaceuticals International, giving Glaxo access to the U.S. company´s experimental epilepsy drug retigabine and other pain treatments. Retigabine has already completed Phase III trials, and may be on the market by 2010. Further details.
Cytokinetics To Test Higher Dose of Experimental Heart Drug
08/28/2008
Cytokinetics, Inc announced the completion of a protocol-defined interim analysis in an ongoing Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina. The experimental drug, a cardiac myosin activator, is being developed with Amgen Inc for the potential treatment of patients with either acutely decompensated or chronic heart failure.
Takeda´s Drug
NEJM: Velcade Helped Untreated Multiple Myeloma Patients
08/28/2008
Alzheimer drug
Barr Announces Favorable Ruling in Razadyne Patent Challenge
08/28/2008
Multikine
Head and Neck Cancer: Teva Licenses Cel-Sci Drug
08/28/2008
Experimental scar reduction treatment
Shire Will Not Push Juvista End-Stage Trials, Says Developer Renovo
08/28/2008
- BLOG
- VIDEOS
- NM Extra
E-Survey by Manhattan Research
Top Ten Internet Brand Web Sites Visited by Primary Care Physicians
08/27/2008
A new study from market research company Manhattan Research reports the top ten Websites visited by physicians, revealing diabetes treatment brands are the products most researched.
Novartis blockbuster for gastrointestinal tumors, leukemia
Glivec/Gleevec Wins FDA Expedited Review as Treatment for After Surgery Removal of Stomach and Intestinal Tumors
08/27/2008
Switzerland´s Novartis AG won an expedited review from U.S. health regulators for an application to sell the cancer drug Glivec/Gleevec for use after surgery to remove stomach and intestinal tumors. Review is lowered from 10 to 6 months. Further details.
Lucentis, for age-related macular degeneration (AMD)
Patients on U.K. National Health Service May Have Access to Novartis´ Eye Drug
08/27/2008
Britain´s healthcare watchdog NICE has recommended Novartis AG´s high-priced injectable eye drug Lucentis for the National Health Service (NHS), under a special plan that will cap the cost of treatment to the state. The scheme allows 14 shots covered by NHS; Novartis covers the cost of any further shots.
